{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"4"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"4"}]}],"title":"Other Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"6"}]}],"title":"No Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"Objective responses by International Working Group criteria: 'Complete Response' (CR) defined as Normalization of the peripheral blood and bone marrow with \\<5% bone marrow blasts, a peripheral blood granulocyte count \\> (1.0 x 109/ L, and a platelet count \\> 100 x 109/L); 'Other Response' including Partial Remission (PR) defined as above, except for the presence of 6-15% marrow blasts, or 50% reduction if \\<15% at start of treatment combined with participants who meet all criteria for CR except for platelet recovery to \\>100 x 109/L; and 'No Response'.","groups":[{"description":"10 mg/m2 by vein (IV) over 1 hour daily for 10 days","id":"OG000","title":"Decitabine 10 mg/m2 IV"},{"description":"20 mg/m2 IV over 1 hour daily for 5 days","id":"OG001","title":"Decitabine 20 mg/m2 IV"},{"description":"20 mg/m2 subcutaneous (SQ) daily for 5 days","id":"OG002","title":"Decitabine 20 mg/m2 SQ"}],"paramType":"NUMBER","populationDescription":"As treated: 124 patients completed treatment.","reportingStatus":"POSTED","timeFrame":"Response to treatment after 8 weeks of therapy","title":"Participant Responses","type":"PRIMARY","unitOfMeasure":"Participants"}